Recursion Pharmaceuticals is cutting approximately 20% of its workforce in response to pipeline pruning and challenging capital markets. After merging with AI drug discovery firm Exscientia, Recursion is streamlining operations, aiming to extend its cash runway into late 2027. These lay-offs reflect broader funding headwinds in biopharma, with continued uncertainty impacting strategic investment and operational scale.